참고문헌
- Arvind R, Shimamoto H, Momose F, et al (2005). A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation. Int J Oncol, 27, 1499-504.
- Bazley LA, Gullick WJ (2005). The epidermal growth factor receptor family. Endocr Relat Cancer, 12, 17-27. https://doi.org/10.1677/erc.1.01032
- de Melker AA, van der Horst G, Borst J (2004). Ubiquitin ligase activity of c-Cbl guides the epidermal growth factor receptor into clathrin-coated pits by two distinct modes of Eps15 recruitment. J Biol Chem, 279, 55465-73. https://doi.org/10.1074/jbc.M409765200
- Caligiuri MA, Briesewitz R, Yu J, et al (2007). Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood, 110, 1022-4. https://doi.org/10.1182/blood-2006-12-061176
- Fekrazad R, Hakimiha N, Farokhi E, et al (2011). Treatment of oral squamous cell carcinoma using anti-HER2 immunonanoshells. Int J Nanomedicine, 6, 2749-55.
- Glogowska A, Stetefeld J, Weber E, et al (2012). Epidermal growth factor cytoplasmic domain affects ErbB protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells. Neoplasia, 14, 396-409.
- Gupta R, Ratan A, Rajesh C, et al (2012). Sequencing and analysis of a South Asian-Indian personal genome. BMC Genomics, 13, 440. https://doi.org/10.1186/1471-2164-13-440
- Jayaraman B, Valiathan GM, Jayakumar K, et al (2012). Lack of mutation in p53 and H-ras genes in phenytoin induced gingival overgrowth suggests its non cancerous nature. Asian Pac J Cancer Prev, 13, 5535-8. https://doi.org/10.7314/APJCP.2012.13.11.5535
- Jiang N, Saba NF, Chen ZG (2012). Advances in targeting her3 as an anticancer therapy. Chemother Res Pract, 817, 304.
- Mahalingam M, Arvind R, Ida H, et al (2008). ERK2 CD domain mutation from a human cancer cell line enhanced anchorage-independent cell growth and abnormality in Drosophila. Oncol Rep, 20, 957-62.
- Mosesson Y, Shtiegman K, Katz M, et al (2003). Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem, 278, 21323-6. https://doi.org/10.1074/jbc.C300096200
- Muramatsu H, Makishima H, Jankowska AM, et al (2010). Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood, 115, 1969-75. https://doi.org/10.1182/blood-2009-06-226340
- Nau MM, Lipkowitz S (2003). Comparative genomic organization of the cbl genes. Gene, 308, 103-13. https://doi.org/10.1016/S0378-1119(03)00471-2
- Ogawa S, Shih LY, Suzuki T, et al (2010). Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms. Clin Cancer Res, 16, 3825-31. https://doi.org/10.1158/1078-0432.CCR-09-2341
- Papagiorgis PC, Zizi AE, Tseleni S, Oikonomakis IN, Nikiteas NI (2012). The pattern of epidermal growth factor receptor variation with disease progression and aggressiveness in colorectal cancer depends on tumor location. Oncol Lett, 3, 1129-35.
- Reich D, Thangaraj K, Patterson N, Price AL, Singh L (2009). Reconstructing Indian population history. Nature, 461, 489-94. https://doi.org/10.1038/nature08365
- Rubin C, Gur G, Yarden Y (2005). Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res, 15, 66-71. https://doi.org/10.1038/sj.cr.7290268
- Ryan PE, Sivadasan-Nair N, Nau MM, Nicholas S, Lipkowitz S (2010). The N terminus of Cbl-c regulates ubiquitin ligase activity by modulating affinity for the ubiquitin-conjugating enzyme. J Biol Chem, 285, 23687-98. https://doi.org/10.1074/jbc.M109.091157
- Sorkin A, Goh LK (2009). Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res, 315, 683-96. https://doi.org/10.1016/j.yexcr.2008.07.029
- Swaminathan G, Tsygankov AY (2006). The Cbl family proteins: ring leaders in regulation of cell signaling. J Cell Physiol, 209, 21-43. https://doi.org/10.1002/jcp.20694
- Tan YH, Krishnaswamy S, Nandi S, et al (2010). CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One, 5, 8972. https://doi.org/10.1371/journal.pone.0008972
- Visser GD, Lill NL (2005). The Cbl RING finger C-terminal flank controls epidermal growth factor receptor fate downstream of receptor ubiquitination. Exp Cell Res, 311, 281-93. https://doi.org/10.1016/j.yexcr.2005.09.015
- Visser Smit GD, Place TL, Cole SL, et al (2009). Cbl controls EGFR fate by regulating early endosome fusion. Sci Signal, 102, 86.
피인용 문헌
- A Novel Heterozygous Mutation (F252Y) in Exon 7 of the IRF6 Gene is Associated with Oral Squamous Cell Carcinomas vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6803
- Tyrosine 1045 Codon Mutations in Exon 27 of EGFR are Infrequent in Oral Squamous Cell Carcinomas vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4279